Bluesight vs Protenus (2026)
Both lead in drug diversion detection, and both grade A on AI centrality, so focus against breadth decides it. Bluesight is the focused market leader: its diversion product holds Best in KLAS three years running, audits a reported 100 million plus medication transactions, and carries the most transparent method in the category, naming unsupervised machine learning and explaining plainly why the simple statistics it replaces fail against diverters who cover their tracks. Protenus is the dual platform: diversion and privacy monitoring run on one engine, so a single purchase serves both the pharmacy and the privacy office, and it holds Best in KLAS in both. The caution is shared and this index grades it C for each: both build behavioural profiles of named clinicians, and both can flag a clinician for practising unusually rather than for diverting, with no published fairness evaluation on either side. If your failure mode is diversion as the whole job with the most transparent method and the longest KLAS run, start with Bluesight. If your failure mode is covering diversion and privacy together, start with Protenus.
- The most transparent method in the category, graded A on model transparency: the company names its technique as unsupervised machine learning and explains plainly why the simple statistics it replaces fail against diverters who conceal their activity, which tells a technically literate buyer how the system behaves.
- The focused diversion leader with the longest independent track record, graded A on AI centrality: Best in KLAS three years running for the diversion product specifically, market share leadership, and a reported 100 million plus medication transactions across more than 1,000 US and Canadian hospitals.
- Low friction deployment, graded A: it leverages existing reports rather than bespoke integrations, with a reported 10 hospital rollout in 33 days with minimal IT involvement, exceptional for a system touching both dispensing cabinets and EMRs.
- Two risk domains from one platform: drug diversion surveillance and patient privacy monitoring share one behavioural engine, so a single purchase covers both the pharmacy and the privacy office, where Bluesight's diversion product is focused on medication alone.
- Independent validation in both domains, graded B on evidence: Best in KLAS in 2023 for both drug diversion surveillance and patient privacy monitoring, rare to win in two categories at once, plus Gartner Cool Vendor recognition.
- Dual profiling as the method, graded A on AI centrality: the platform builds profiles of both patients and accessing users and reasons about appropriateness, with the same engine trained differently for diversion and privacy, protected by granted patents.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Bluesight and Protenus are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Bluesight | Protenus |
|---|---|---|
| Primary category | Healthcare Cybersecurity | Healthcare Cybersecurity |
| Founded | 2011 | 2014 |
| Headquarters | Alexandria, Virginia, United States | Baltimore, Maryland, United States |
| Website | bluesight.com | protenus.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Bluesight its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and EHR and Interoperability Depth. Set against Protenus, Bluesight grades higher on Model and Technology Transparency and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Protenus its top capability grade on AI Centrality and EHR and Interoperability Depth. Set against Bluesight, Protenus grades higher on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Bluesight or Protenus?
On the axes where the AI Health Index separates them, Bluesight grades higher on Model and Technology Transparency and Deployment Model and Data Residency, and Protenus grades higher on Model Supply Chain Disclosure. Bluesight leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Bluesight and Protenus differ most?
The widest separation the AI Health Index records between Bluesight and Protenus is on Model and Technology Transparency, where Bluesight grades A and Protenus grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Bluesight and Protenus grade the same?
The AI Health Index grades Bluesight and Protenus the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Healthcare Administrative Automation page.
Both grade A on AI centrality and are strong on diversion specifically; the split is focus against breadth. Bluesight is the diversion market leader with three consecutive years of Best in KLAS for that product and the most transparent published method in the category, graded A on model transparency for naming unsupervised learning and explaining why simpler statistics fail, where Protenus grades B. Protenus covers privacy as well as diversion from one platform, with Best in KLAS in both, which Bluesight's medication focus does not match.
The governance caution applies equally to both and is graded C for each: these are workforce surveillance products, and unsupervised anomaly detection flags statistical outliers, so a clinician whose legitimate practice differs from a thin peer group, through specialty, shift, or a small unit, can be flagged for being unusual rather than for diverting, and neither publishes a fairness evaluation or false accusation rate. Neither publishes a security attestation or pricing.